Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Oliver-Caldes A, Español-Rego M, Zabaleta A, González-Calle V, Navarro-Velázquez S, Inogés S, de Cerio AL, Cabañas V, López-Muñoz N, Rodríguez-Otero P, Reguera JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosiñol L, Cid J, Tovar N, Sáez-Peñataro J, López-Parra M, Olesti E, Guillén E, Varea S, Rodríguez-Lobato LG, Battram AM, González MS, Sánchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prósper F, Juan M, Martínez-López J, Moraleda JM, Mateos MV, Urbano-Ispizua Á, Paiva B, Pascal M, Fernández de Larrea C. Oliver-Caldes A, et al. Among authors: moraleda jm. Clin Cancer Res. 2024 May 15;30(10):2085-2096. doi: 10.1158/1078-0432.CCR-23-3759. Clin Cancer Res. 2024. PMID: 38466644
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: moraleda jm. Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241. Blood. 2019. PMID: 31484647 Free PMC article. Clinical Trial.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: moraleda jm. Blood Adv. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. Blood Adv. 2020. PMID: 32433744 Free PMC article.
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study.
Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, Sagredo V, Álvarez-Avello JM, Guerrero JE, Pérez-Calvo C, Sánchez-Hernández MV, Del-Pozo JL, Andreu EJ, Fernández-Santos ME, Soria-Juan B, Hernández-Blasco LM, Andreu E, Sempere JM, Zapata AG, Moraleda JM, Soria B, Fernández-Avilés F, García-Olmo D, Prósper F. Sánchez-Guijo F, et al. Among authors: moraleda jm. EClinicalMedicine. 2020 Aug;25:100454. doi: 10.1016/j.eclinm.2020.100454. Epub 2020 Jul 10. EClinicalMedicine. 2020. PMID: 32838232 Free PMC article.
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome.
Fernández-Santos ME, Garcia-Arranz M, Andreu EJ, García-Hernández AM, López-Parra M, Villarón E, Sepúlveda P, Fernández-Avilés F, García-Olmo D, Prosper F, Sánchez-Guijo F, Moraleda JM, Zapata AG. Fernández-Santos ME, et al. Among authors: moraleda jm. Front Immunol. 2022 Jun 9;13:918565. doi: 10.3389/fimmu.2022.918565. eCollection 2022. Front Immunol. 2022. PMID: 35812460 Free PMC article. Review.
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV).
Sánchez-Guijo F, Avendaño-Solá C, Badimón L, Bueren JA, Canals JM, Delgadillo J, Delgado J, Eguizábal C, Fernández-Santos ME, García-Olmo D, González-Aseguinolaza G, Juan M, Martín F, Mata R, Montserrat N, Pérez-Martínez A, Pérez-Simón JA, Prósper F, Urbano-Ispizua Á, Zapata AG, Sureda A, Moraleda JM. Sánchez-Guijo F, et al. Among authors: moraleda jm. Bone Marrow Transplant. 2023 Jun;58(6):727-728. doi: 10.1038/s41409-023-01962-0. Epub 2023 Mar 25. Bone Marrow Transplant. 2023. PMID: 36966215 Free PMC article. No abstract available.
Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis.
Poveda-García A, Ruiz E, Moreno MJ, Español I, Sánchez-Salinas A, García-Hernández AM, Blanquer M, Martínez I, Sánchez-Villalobos M, García Garay MC, Salido E, Heredia Á, Navarro-Almenzar B, Monserrat J, Sánchez-Salas JA, Martínez-Mellado AJ, Minguela A, Campillo JA, López-Hernández R, Galián JA, Moraleda JM, Roldán V, Cabañas V. Poveda-García A, et al. Among authors: moraleda jm. Bone Marrow Transplant. 2024 Nov;59(11):1625-1627. doi: 10.1038/s41409-024-02404-1. Epub 2024 Aug 26. Bone Marrow Transplant. 2024. PMID: 39187602 No abstract available.
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat JC, Gonzalez-Calle V, Moreno DF, Cabañas V, Lopez-Muñoz N, Bartolome-Solanas A, Español-Rego M, Reguera-Ortega JL, Rosiñol L, Lopez-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EAA, Martínez-López J, Mateos MV, Tomas X, Setoain X, Fernández de Larrea C. Zugasti I, et al. Among authors: moraleda jm. Blood Adv. 2024 Nov 27:bloodadvances.2024014360. doi: 10.1182/bloodadvances.2024014360. Online ahead of print. Blood Adv. 2024. PMID: 39602341
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Moscardó F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C, Solano C, Pimentel P, Pérez de Oteyza J, Ferrá C, Díez-Martín JL, Zuazu J, Espigado I, Campilho F, Arbona C, Moraleda JM, Mateos MV, Sierra J, Talarn C, Sanz MA. Moscardó F, et al. Among authors: moraleda jm. Exp Hematol. 2003 Jun;31(6):545-50. doi: 10.1016/s0301-472x(03)00070-5. Exp Hematol. 2003. PMID: 12829031 Free article. Clinical Trial.
An automatic wash method for dimethyl sulfoxide removal in autologous hematopoietic stem cell transplantation decreases the adverse effects related to infusion.
Sánchez-Salinas A, Cabañas-Perianes V, Blanquer M, Majado MJ, Insausti CL, Monserrat J, Sánchez-Ibáñez MV, Menchón P, García-Hernández A, Gómez-Espuch J, Morales A, Moraleda JM. Sánchez-Salinas A, et al. Among authors: moraleda jm. Transfusion. 2012 Nov;52(11):2382-6. doi: 10.1111/j.1537-2995.2012.03585.x. Epub 2012 Mar 8. Transfusion. 2012. PMID: 22404870 Clinical Trial.
237 results